Apricus Biosciences Inc (NASDAQ:APRI)’s Stock Is Buy After Less Market Selling

September 16, 2018 - By Sheila Anderson

The stock of Apricus Biosciences Inc (NASDAQ:APRI) registered a decrease of 2.54% in short interest. APRI’s total short interest was 1.14M shares in September as published by FINRA. Its down 2.54% from 1.17M shares, reported previously. With 415,000 shares average volume, it will take short sellers 3 days to cover their APRI’s short positions.

The stock decreased 0.17% or $0.0005 during the last trading session, reaching $0.2866. About 236,006 shares traded. Apricus Biosciences, Inc. (NASDAQ:APRI) has declined 82.06% since September 16, 2017 and is downtrending. It has underperformed by 97.68% the S&P500.

Apricus Biosciences, Inc., a biopharmaceutical company, focuses on the development and commercialization of product candidates in the areas of urology and rheumatology. The company has market cap of $6.72 million. The Company’s lead product is Vitaros, a topically-applied cream formulation of alprostadil used for the treatment of erectile dysfunction. It currently has negative earnings. The firm also engages in developing RayVa, which is in Phase 2 development for the treatment of RaynaudÂ’s Phenomenon associated with scleroderma; and Fispemifene, a tissue-specific selective estrogen receptor modulator for the treatment of secondary hypogonadism, chronic prostatitis, and lower urinary tract symptoms in men.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.